Palmer Abigail A, Stezoski Jason P, Janesko-Feldman Keri, Kochanek Patrick M, Drabek Tomas
Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.
Department of Graduate Medical Education, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Exp Ther Med. 2022 Jun;23(6):380. doi: 10.3892/etm.2022.11307. Epub 2022 Apr 8.
Cardiac arrest (CA) results in a central and systemic cytokine and inflammatory response. Thalidomide has been reported to be neuroprotective by selectively decreasing TNFα synthesis. We hypothesized that thalidomide would decrease the systemic and organ-specific TNFα/cytokine response and biomarkers of injury in rats subjected to 10 min CA. Naïves, CA treated with vehicle (CA) and CA treated with thalidomide (50 mg/kg; CA+T) were studied (n=6 per group). TNFα and key cytokines were assessed at 3 h after resuscitation in the cortex, hippocampus, striatum, cerebellum, plasma, heart and lung. Neuron specific enolase (NSE), S100b, cardiac troponin T (cTnT) and intestinal fatty acid binding protein (IFABP) were used to assess neuronal, glial, cardiac and intestinal damage, respectively. CA increased TNFα and multiple pro-inflammatory cytokines in plasma and selected tissues with no differences between the CA and CA+T groups in any region. NSE, S100b, cTnT and IFABP were increased after CA or CA+T vs. in the naïve group (all P<0.05) without significant differences between the CA and CA+T groups. In conclusion, CA resulted in a TNFα and cytokine response, with increased biomarkers of organ injury. Notably, thalidomide at a dose reported to improve the outcome in models of brain ischemia did not decrease TNFα or cytokine levels in plasma, brain or extracerebral organs, or biomarkers of injury. Although CA at 3 h post resuscitation produces a robust TNFα response, it cannot be ruled out that an alternative dosing regimen or assessment at other time-points might yield different results. The marked systemic and regional cytokine response to CA remains a potential therapeutic target.
心脏骤停(CA)会引发中枢性和全身性细胞因子及炎症反应。据报道,沙利度胺可通过选择性降低肿瘤坏死因子α(TNFα)的合成起到神经保护作用。我们推测沙利度胺会降低经历10分钟心脏骤停的大鼠的全身及器官特异性TNFα/细胞因子反应以及损伤生物标志物水平。研究了未处理组、用赋形剂处理的心脏骤停组(CA组)和用沙利度胺处理的心脏骤停组(50毫克/千克;CA + T组)(每组n = 6)。复苏后3小时,在皮质、海马体、纹状体、小脑、血浆、心脏和肺中评估TNFα及关键细胞因子。分别使用神经元特异性烯醇化酶(NSE)、S100b、心肌肌钙蛋白T(cTnT)和肠脂肪酸结合蛋白(IFABP)来评估神经元、神经胶质、心脏和肠道损伤。心脏骤停使血浆和选定组织中的TNFα及多种促炎细胞因子增加,CA组和CA + T组在任何区域均无差异。与未处理组相比,心脏骤停组或CA + T组后NSE、S100b、cTnT和IFABP均升高(所有P < 0.05),CA组和CA + T组之间无显著差异。总之,心脏骤停引发了TNFα和细胞因子反应,同时器官损伤生物标志物增加。值得注意的是,据报道在脑缺血模型中能改善预后的剂量的沙利度胺并未降低血浆、脑或脑外器官中的TNFα或细胞因子水平,也未降低损伤生物标志物水平。尽管复苏后3小时的心脏骤停会产生强烈的TNFα反应,但不能排除其他给药方案或在其他时间点进行评估可能会产生不同结果。心脏骤停引发的显著全身和局部细胞因子反应仍是一个潜在的治疗靶点。